Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
  • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
  • Contact Us
  • Menu Menu
You are here: Home

Developing T cell-priming immune set-point candidates against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy and clear pathogen-infected cells.

Introducing Emergex

Emergex is a clinical-stage, privately held biotechnology company headquartered in Oxfordshire, Abingdon, UK, with R&D facilities in Milton Park, UK, an operating subsidiary in Doylestown, Pennsylvania, and a GMP capable manufacturing facility in Fremont, CA, USA. Emergex is pioneering the development of a range of 100% synthetic CD8+ T cell-priming immune set-point candidates designed to harness the body’s natural cellular immune response to destroy pathogen-infected cells and to provide broad and robust immune protection for some of the world’s most urgent infectious diseases.


Our Technology Vaccine Advantages

We work on addressing some of the world’s most impactful health threats with a growing pipeline of candidates. Emergex’s T cell-priming immune set-point candidates combine two proprietary technologies. Our lead candidates protect against infectious diseases caused by: (1) viruses, causing diseases such as Dengue Fever, Betacoronavirus, and Universal Influenza A (including pandemic influenza); as well as (2) intra-cellular bacteria, including Francisella tularensis.

Our Vision:

To positively impact global human health though the development of innovative T cell-priming product candidates for some of the world’s most immediate health threats.

Our Technology Vaccine Advantages

Latest press releases

Emergex Signs Contract of £1,79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus

17th November 2023
Read more
/wp-content/uploads/2018/01/logo.png 0 0 gatekeeper /wp-content/uploads/2018/01/logo.png gatekeeper2023-11-17 12:00:202023-11-17 16:48:28Emergex Signs Contract of £1,79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus

Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have signed MoU to Advance First-of-its-Kind Infectious Disease Solutions

5th October 2023
Read more
/wp-content/uploads/2018/01/logo.png 0 0 gatekeeper /wp-content/uploads/2018/01/logo.png gatekeeper2023-10-05 12:00:212023-10-05 14:04:58Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have signed MoU to Advance First-of-its-Kind Infectious Disease Solutions

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

19th July 2023
Read more
/wp-content/uploads/2018/01/logo.png 0 0 gatekeeper /wp-content/uploads/2018/01/logo.png gatekeeper2023-07-19 13:00:082023-10-12 10:15:19Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
Our Technology Vaccine Advantages

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top